Effects of add-on montelukast on airway hyperresponsiveness in patients with well-controlled asthma - a pilot study.

ABSTRACT: OBJECTIVE:Control of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess the effects of a leukotriene receptor antagonist (LTRA) added to a basic treatment of inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) on airway hyperresponsiveness, inflammation, and quality of life in well-controlled patients with asthma. RESEARCH DESIGN AND METHODS:Seventeen patients (age 18-65, 11 women) with well-controlled asthma presenting airway hyperresponsiveness to mannitol and methacholine challenge were given add-on montelukast on a stable ICS?+?LABA for 4 weeks. Quality of life and selected parameters of airway inflammation were measured at baseline and at study end. (ClinicalTrials.gov (NCT01725360)). RESULTS:Adding montelukast to ICS?+?LABA resulted in an increase in mean FEV1 (+4.5%, p?=?0.057), cumulated higher dose of mannitol (+32.5%, p?=?0.023) and methacholine (+17.2%, 0.237) in the provocation test, lower airway reactivity with mannitol and methacholine (response dose ratio (RDR) -50.0%, p?=?0.024 and -44.3%, p?=?0.006, respectively), and improved airway sensitivity to mannitol and methacholine (+12.1%, p?=?0.590 and +48.0%, p?=?0.129 for PD15 and PD20 FEV1, respectively). Changes in inflammation parameters (blood eosinophil count, serum eosinophil cationic protein, and exhaled nitric oxide) were consistent with these findings. Asthma-related quality of life improved significantly in all domains and overall (from 5.3 at baseline to 6.1 at the final visit, p?

SUBMITTER: Kononowa N 

PROVIDER: S-EPMC4937661 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature